ArticleFrontiers in immunology2025
Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host Immune Response Mechanisms Against Herpes Simplex Virus Type 2 Infection.Pathogens (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The globally prevalent herpes simplex virus 2 (HSV-2) establishes lifelong latent infections in sensory neurons and causes recurrent genital disease. However, no vaccine is available to prevent HSV-2 infection. The mRNA vaccine platform offers distinct advantages over protein-based approaches, including rapid antigen design, scalable production, and efficient intracellular expression. Methods: A prophylactic quadrivalent mRNA vaccine encoding full-length HSV-2 glycoprotein B (gB2), C (gC2), D (gD2), and E (gE2) was developed. Its immunogenicity and protective efficacy were evaluated in a murine intravaginal challenge model. Results: Quadrivalent mRNA vaccine-immunized mice showed robust HSV-2-specific immune responses, including high titers of neutralizing antibodies and strong T cell responses, which persisted for at least 16 weeks. Upon viral challenge, vaccinated animals were fully protected from genital disease and exhibited significantly reduced viral copy numbers in the genital tract. Vaccination also inhibited the establishment of latent infections in the dorsal root ganglia, as evidenced by markedly lower HSV-2 DNA levels than those in mock-vaccinated controls. Comparative analysis showed no significant difference between co-formulated and admixed lipid nanoparticle formulations, indicating flexibility in vaccine manufacturing without compromising efficacy. Discussion: The quadrivalent mRNA vaccine provides strong and durable protection against both primary and latent infection, supporting its potential as a promising candidate for the prevention of genital herpes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.